RASGRP2 (NM_001098671) Human Mass Spec Standard

CAT#: PH312719

RASGRP2 MS Standard C13 and N15-labeled recombinant protein (NP_001092141)



  View other "RASGRP2" proteins (11)

Need it in bulk or customized?
Get a free quote

CNY 19,520.00


货期*
4周

规格
    • 10 ug

Product images

经常一起买 (2)
Rabbit polyclonal RASGRP2 Antibody (N-term)
    • 400 ul

CNY 6,160.00


Transient overexpression lysate of RAS guanyl releasing protein 2 (calcium and DAG-regulated) (RASGRP2), transcript variant 2
    • 100 ug

CNY 4,840.00

Specifications

Product Data
Description RASGRP2 MS Standard C13 and N15-labeled recombinant protein (NP_001092141)
Species Human
Expression Host HEK293
Expression cDNA Clone or AA Sequence RC212719
Predicted MW 69.2 kDa
Protein Sequence
Tag C-Myc/DDK
Purity > 80% as determined by SDS-PAGE and Coomassie blue staining
Concentration >0.05 µg/µL as determined by microplate BCA method
Labeling Method Labeled with [U- 13C6, 15N4]-L-Arginine and [U- 13C6, 15N2]-L-Lysine
Buffer 25 mM Tris-HCl, 100 mM glycine, pH 7.3
Reference Data
RefSeq NP_001092141
RefSeq Size 2284
RefSeq ORF 1827
Synonyms CALDAG-GEFI; CDC25L
Locus ID 10235
Cytogenetics 11q13.1
Summary The protein encoded by this gene is a brain-enriched nucleotide exchanged factor that contains an N-terminal GEF domain, 2 tandem repeats of EF-hand calcium-binding motifs, and a C-terminal diacylglycerol/phorbol ester-binding domain. This protein can activate small GTPases, including RAS and RAP1/RAS3. The nucleotide exchange activity of this protein can be stimulated by calcium and diacylglycerol. Four alternatively spliced transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jan 2016]
Protein Pathways Chemokine signaling pathway, MAPK signaling pathway
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...